Published 11 days ago • loading... • Updated 11 days ago

Tiger BioSciences Spotlights Major Clinical and Scientific Milestones Following Significant 2025 Research Investment

Tiger BioSciences issued a PR Newswire release from Conshohocken, Pa., highlighting major clinical and scientific milestones after expanding its 2025 research investments.
In 2025, the company expanded its investment in evidence-based research to support clinical programs using its recovery, processing, technology development, research and distribution capabilities.
Evidence cited includes retrospective studies and an ongoing RCT with early positive signals, as Tiger supported five peer-reviewed retrospective clinical studies in 2025 and launched a prospective randomized controlled trial for diabetic foot ulcers and venous leg ulcers.
Executives argue the evidence positions Tiger BioSciences as market leader heading into 2026, and Garrett Grinsfelder said `We believe that meaningful clinical evidence is the foundation of longterm innovation in wound care`.
Tiger BioSciences will expand its clinical research program with an RCT on pressure ulcer care and expects two active RCTs in 2026, company executives say caregraFT shows early promise.

Insights by Ground AI

32 Articles

Bennington Banner

+31 Reposted by 31 other sources

Center

Tiger BioSciences Spotlights Major Clinical and Scientific Milestones Following Significant 2025 Research Investment

CONSHOHOCKEN, Pa., Dec. 30, 2025 /PRNewswire/ -- Tiger BioSciences highlights a series of major clinical and scientific achievements resulting from the company's expanded investment in evidence‑based research throughout 2025. This strategic focus has strengthened Tiger BioSciences' position as a market…

11 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year